Reactions Weekly

, Volume 1722, Issue 1, pp 156–156 | Cite as

Fingolimod withdrawal

Rebound of multiple sclerosis: 5 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective, observational, real-life study of 100 patients, five women [exact ages at reaction onsets not stated] were described, who developed rebound of multiple sclerosis (MS) after discontinuation of fingolimod therapy for MS [dosages, routes and outcomes not stated].

Patient 1: A woman was diagnosed with MS at the age of 20 years. Five years after MS diagnosis, she started receiving treatment with fingolimod for relapsing-remitting MS. Thereafter, her fingolimod therapy was discontinued due to the desire of pregnancy. Expanded Disability Status Scale (EDSS) was 2 at the time of fingolimod discontinuation. Two months after fingolimod discontinuation, her lymphocytes count was 1200 /µL. Brain MRI findings revealed T2 lesions and Gd+ lesions. EDSS at the of...


  1. Frau J, et al. Clinical activity after fingolimod cessation: disease reactivation or rebound? European Journal of Neurology 25: 1270-1275, No. 10, Oct 2018. Available from: URL: - ItalyCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations